Maia Biotechnology, INC Form 4 insider transactions

Steven M. Chaouki, a director of MAIA Biotechnology, Inc., acquired 20,667 stock options on April 4, 2025, which vest immediately.

Director Ramiro Guerrero reports acquisition of stock options in MAIA Biotechnology, Inc.

Director Louie Ngar Yee reports acquisition of stock options in MAIA Biotechnology, Inc.

Cristian Luput, a director at MAIA Biotechnology, Inc., acquired 21,042 stock options on April 4, 2025, according to a Form 4 filing.

Director Jean-Manasse Theagene acquired 20,291 stock options in MAIA Biotechnology, Inc. on April 4, 2025.

Director Ramiro Guerrero increased his holdings in MAIA Biotechnology through the purchase of common stock and warrants on March 3, 2025.

Director Stan Smith reports purchasing 25,000 shares of MAIA Biotechnology and warrants for the same amount, signaling increased confidence in the company.

Director Stan Smith files an amended Form 4 to correct the exercisable and expiration dates of warrants and the date of the Securities Purchase Agreement related to a recent transaction.

Ramiro Guerrero, a director at MAIA Biotechnology, Inc., filed an amended Form 4 to correct the exercisable and expiration dates of warrants and the date of the Securities Purchase Agreement.

Director Ramiro Guerrero purchased 73,333 shares of common stock and warrants of MAIA Biotechnology, Inc. on February 24, 2025.

Director Stan Smith purchased 50,000 shares of MAIA Biotechnology and related warrants, increasing his indirect beneficial ownership.

Sergei Gryaznov, Chief Scientific Officer of MAIA Biotechnology, Inc., reports the acquisition of 200,000 stock options on February 10, 2025.

Vlad Vitoc, CEO of MAIA Biotechnology, Inc., reports the acquisition of 400,000 stock options on February 10, 2025, according to a Form 4 filing with the SEC.

Jeffrey Himmelreich, Head of Finance at MAIA Biotechnology, Inc., reports the acquisition of stock options.

Director Cristian Luput acquired 10,225 stock options in MAIA Biotechnology, Inc. on December 31, 2024.

Director Ramiro Guerrero reports acquiring 10,225 stock options in MAIA Biotechnology, Inc. on December 31, 2024.

Director Louie Ngar Yee acquired 15,338 stock options in MAIA Biotechnology, Inc. on December 31, 2024.

Director Stan Smith reports acquisition of stock options in MAIA Biotechnology through a recent Form 4 filing.

Director Steven M. Chaouki reports acquisition of stock options in MAIA Biotechnology, Inc.

A director of MAIA Biotechnology, Inc. acquired 10,225 stock options on December 31, 2024, which vest immediately.

Director Stan Smith of MAIA Biotechnology, Inc. purchased 25,000 shares of common stock and 25,000 warrants on December 13, 2024.

Ramiro Guerrero, a director at MAIA Biotechnology, purchased 53,418 shares of common stock and warrants on December 13, 2024.

Vlad Vitoc, CEO of MAIA Biotechnology, gifted stock options to irrevocable trusts for the benefit of his children, disclaiming beneficial ownership except for his pecuniary interest.

Director Cristian Luput purchased shares and warrants of MAIA Biotechnology, Inc. on November 1, 2024, according to a Form 4 filing.

Director Steven M. Chaouki purchased 22,133 shares of common stock and warrants of MAIA Biotechnology, Inc. on November 1, 2024.

Director Ramiro Guerrero purchased MAIA Biotechnology common stock and warrants on November 1, 2024.

Director Stan Smith purchased 100,000 shares of MAIA Biotechnology and related warrants on November 1, 2024, increasing his indirect holdings.

Director Steven M. Chaouki reports acquisition of stock options in MAIA Biotechnology, Inc.

Director Stan Smith reports acquisition of stock options in MAIA Biotechnology through a Form 4 filing with the SEC.

Director Ramiro Guerrero reports acquisition of stock options in MAIA Biotechnology, Inc.